Merck takes on the TROP2 leaders again in breast cancer
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
